Hepatitis C and injecting drug use: impact, costs and policy options
Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication pres...
| Otros Autores: | |
|---|---|
| Tipo de documento: | Electrónico Libro |
| Lenguaje: | Inglés |
| Publicado: |
Luxemburg
Office for Official Publications of the European Communities
2004
|
| En: |
EMCDDA scientific monograph series (7)
Año: 2004 |
| Acceso en línea: |
Volltext (kostenfrei) Volltext (kostenfrei) Volltext (kostenfrei) |
| Verificar disponibilidad: | HBZ Gateway |
| Palabras clave: | |
| Publicación relacionada: | Erscheint auch als:
471720607 |
| Sumario: | Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy. Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine. |
|---|---|
| Descripción Física: | 1 Online-Ressource (391 Seiten) |
| DOI: | 10.15496/publikation-23211 |